Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in Alopecia Totalis/Universalis
NCT01314495Phase 2Withdrawn
- Start
- Sep 2011
- Primary completion
- Jun 2012
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 2, randomised, double-blind trial in alopecia totalis (AT) and alopecia universalis (AU) comparing Abatacept with Placebo (2 arms). Primary endpoint: Proportion of responders (>=50% hair re-growth) at 24 weeks. Planned start Sep 2011; status: withdrawn.
02
Drugs
abatacept
03
Conditions
alopecia totalis (AT)alopecia universalis (AU)
Beyond the preview
Go deeper on NCT01314495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01314495.